| Speakers from |
 |
|
Abbott
Amgen
AstraZeneca
Bayer Healthcare
Bio-Modeling Systems
Definiens AG
EMEA
F. Hoffmann-La Roche
GlaxoSmithKline
Ingenuity Systems
Innsbruck University
Institute for Women’s Health, UCL
Johnson & Johnson
Lundbeck
Merck
Millipore
National Institute of Standards & Technology
NeuroSearch
Novartis
Olink Bioscience
Pfizer
Rules Based Medicine
Ryerson University
Schering-Plough
The Critical Path Institute
The Institute of Cancer Research
UCB Group
University College Dublin
Uppsala University
|
|
|
|
|
| Featured Speakers |
|
|
|
Matthew L. Albert,
Head of Lab, Dendritic Cell Immunobiology, Director, Center for Human Immunology, Institut Pasteur
|
 |
|
|
Alison Banham,
Nuffield Department of Clinical Laboratory Sciences, Oxford University
|
|
|
|
Chris Chamberlain,
Medical Director Personalised Medicine Astrazeneca
|
|
|
|
Dan Chelsky,
Cheif Scientific Officer, Caprion Proteomics Inc.
|
|
|
|
Gary Coulton,
Director, St. George's Medical Biomics Centre, St. George's University of London
|
|
|
|
Ratko Djukanovic,
Professor in Respiratory Medicine, Director of the NHR Respiratory Biomedical Research Unit, Southampton Univeristy
|
|
|
|
Nicholas Dracopoli,
Vice President, Centocor Research & Development
|
|
|
|
Jeff Evans,
CRUK Professor of Translational Cancer Research, University of Glasgow
|
|
|
|
Aiden Flynn,
Director Biomarkers and Analytics, GlaxoSmithKline
|
|
|
|
Neil French,
Senior Scientific Operations Manager, MRC Centre for Drug Safety Science, Department of Pharmacology & Therapeutics, The University of Liverpool
|
|
|
|
Steve Furlong,
Safety Science Lead, AstraZeneca Clinical Development
|
|
|
|
Craig Gelfand,
Director, Advanced Technologies, Diagnostics - Preanalytical Systems, BD Diagnostics
|
|
|
|
Geoff Hale,
Managing Director BioPharma Services Europe, Millipore
|
|
|
|
Brett Hall,
Team Lead Biomarkers, Janssen Pharmaceutica (a division of J&J)
|
|
|
|
Thomas Herget,
Senior Director, New Technology Evaluation, Division Chemicals R&D, Merck KGaA
|
|
|
|
Andrew Hughes,
Worldwide Director Early Phase Oncology Clinical Development, Astrazeneca
|
|
|
|
Patricia Hurley,
Head of Project Management and Biomarkers Division, ERA Consulting (UK) Ltd
|
|
|
|
Mark Jones,
Associate Director Molecular Biomarkers, Global Exploratory Development, UCB New Medicines
|
|
|
|
Francis Kalush,
Network Leader for the Diagnostics (In Vivo and In Vitro) and Personalized Medicine Network, FDA
|
|
|
|
Martina Kaufmann,
Biomarker Project Leader, Head Oncology Biomarkers & Imaging, Novartis
|
|
|
|
Andreas Keller,
Head of Genomic Services, Febit
|
|
|
|
Richard Kennedy,
VP of Experimental Medicine, Almac Diagnositcs
|
|
|
|
Iain Kilty,
Director Allergy & Respoiratoy Research Unit, Pfizer
|
|
|
|
Sabine Küsters,
Director of Scientific Relations, Rules Based Medicine
|
|
|
|
Jennifer Larsen,
Translational Medicine Scientist, Lundbeck
|
|
|
|
Mike Lau,
Prinicipal Clinical Development Scientist, GSK Oncology
|
|
|
|
Mark Lindsay,
Reader in Biopharmaceutics, Manchester University
|
|
|
|
Theo Luider,
Head of the Laboratories of Neuro-Oncology, Department of Neurology, Erasmus, University of Rotterdam
|
|
|
|
Duncan McHale,
Vice President, Medical Director Personalized Healthcare, Astrazeneca
|
|
|
|
Huseyin Mehmet,
Director Exploratory Biomarkers, Diabetes, Merck Research Laboratories
|
|
|
|
Gino Miele,
Associate Director, Head of Genomics, Wyeth
|
|
|
|
Samila Mihindukulasuriya,
Senior Contract Analyst, Biomarkers, GSK
|
|
|
|
Sterghios Moschos,
Prinicipal Scientist, Biotherapeutics, Pfizer
|
|
|
|
Samual Murray,
President, Greek Society of Molecular Oncology, University of Ioannina Cancer Biobank
|
|
|
|
Valerie Nedbal,
JMP Pharmaceutical Technical, Manager, SAS Institute France
|
|
|
|
Roger Palframan,
Director of Cellular Sciences, UCB
|
|
|
|
Harsukh Parmar,
Director, Global Discovery medicine, Respiratory & Inflammation Therapy Area, Astrazeneca
|
|
|
|
Maribeth Raines,
Director, Scientific Affairs Valencia, California, USA, Quest Diagnostics
|
|
|
|
Simon Read,
Leader Biomarker and Experimental Medicine, F. Hoffmann - La Roche
|
|
|
|
David Reynolds,
Senior Director, Experimental Biological Sciences, Pfizer
|
|
|
|
Henry Rodriguez,
Clinical Proteomic Technologies for Cancer, Office of the Director, National Cancer Institute
|
|
|
|
Sanja Selak,
Head of Serology and Immune Assays Department, InterCell AG
|
|
|
|
Jonathan Sheldon,
Director of Translational Medicine, IDBS
|
|
|
|
Matt Squires,
Associate Director Translational Biology, Astex Therapeutics
|
|
|
|
Linda Surh,
CEDD Global Regulatory Affairs, Neurosciences and Pharmacogenetics, GlaxoSmithKline
|
|
|
|
Miro Venturi,
Senior Biomarker & Experimental Medicine Leader, Roche Pharma Development
|
|
|
|
Kristof Vercruysse,
Associate Director Clinical Operations, Ablynx
|
|
|
|
Robert Wilkinson,
Prinicpal Scientist, Cancer and Infection Research Area, Astrazeneca
|
|
|
|
Ian Wilson,
Senior Principal Scientist, Department of Drug Metabolism and Pharmacokinetics, Astrazeneca
|
|
|
|
Christer Wingren,
Assistant Professor, Department of Immunotechnology, Lund University, Sweden
|
|
|
|
Hans Winkler,
Senior Director, Global Head Oncology Biomarkers, Ortho Biotech - Johnson & Johnson
|
|
|
|
|
|
